Log-in / Create Account  
 
DIA 2013 49th Annual Meeting
Click here to go to the previous page
Off-target Blood Pressure Changes and Evaluation in Drug Development: Safety, Clinical and Regulatory Considerations
Track : Track 14: Clinical Safety and Pharmacovigilance
Program Code: 428
Date: Thursday, June 27, 2013
Time: 10:45 AM to 12:15 PM  EST
Location: 154
CHAIR :
 Jeffrey Heilbraun, MS (SCHNON), Director Strategic Development, BioClinica Inc., United States
SPEAKER (S):
 Mary Jane Geiger, (SPKNON), Pharmaceutical Consultant, United States
Alison Schecter, MD, FACC, Novartis Institutes of Biomedical Research
Description
There has been an increased focus on changes in blood pressure (BP) related to cardiac safety from a regulatory perspective. This session will provide insight into the "off-target" BP response of drugs outside of cardiovascular drugs from a development and regulatory perspective.

Session Recording
(Code: 428)
DIA 2013 Attendee:
Attendees Login
  
This session is a part of:
DIA 2013 Live Learning Center
CON5 Comp Access: Thursday Online Access Package - June 27, 2013
Handout Online
(Code: 428)
DIA 2013 Attendee:
Attendees Login
  
This session is a part of:
DIA 2013 Live Learning Center
CON5 Comp Access: Thursday Online Access Package - June 27, 2013
Off-target Blood Pressure Changes and Evaluation in Drug Development: Safety, Clinical and Regulatory Considerations